Sign In
Buy BIO
$301.90
-2.46 (-0.81%)
At Close: Jul 20, 2026
Bio-Rad (BIO) International Revenue Performance Explored
10:15am, Wednesday, 26'th Feb 2025
Review Bio-Rad's (BIO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of bluebird bio
BIO Stock Might Rise Following the Offer to Acquire Stilla
08:30am, Tuesday, 18'th Feb 2025
Bio-Rad offers to acquire all equity interests of Stilla Technology. The acquisition is expected to complement Bio-Rad's existing digital PCR portfolio.
BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket
03:01pm, Friday, 14'th Feb 2025
Bio-Rad witnesses growth across the Clinical Diagnostics segment in the fourth quarter, primarily driven by an increased demand for quality control and blood typing products.
Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript
11:45pm, Thursday, 13'th Feb 2025
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Jon DiVincenzo - President
Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates
06:46pm, Thursday, 13'th Feb 2025
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.90 per share, missing the Zacks Consensus Estimate of $2.93 per share. This compares to earnings of $3.10 per share a year ago.
Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results
04:20pm, Thursday, 13'th Feb 2025
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t
Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies
04:15pm, Thursday, 13'th Feb 2025
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company has en
Oncocyte Prices $29.1 Million Equity Offering
08:30am, Monday, 10'th Feb 2025
IRVINE, Calif., Feb. 10, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements
Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference
08:00am, Friday, 07'th Feb 2025
HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generati
Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline
11:06am, Thursday, 06'th Feb 2025
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference
07:00am, Wednesday, 05'th Feb 2025
CHATHAM, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of develop
Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?
10:45am, Tuesday, 04'th Feb 2025
Here is how Bio-Rad Laboratories (BIO) and Certara, Inc. (CERT) have performed compared to their sector so far this year.
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference
06:50am, Tuesday, 04'th Feb 2025
Corporate presentation scheduled for Tuesday, February 11, 2025 at 10:15 AM EST CARMIEL, Israel , Feb. 4, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical
Lifecore Biomedical to Participate in 2025 BIO CEO & Investor Conference
07:00am, Monday, 03'rd Feb 2025
CHASKA, Minn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today a
